The global vaccine group Gavi said on Monday it hopes to use $600 million in soon-to-be-restored U.S. funding to boost malaria and other vaccination efforts, as it also meets U.S. conditions over phasing out the preservative thimerosal in other vaccines in its portfolio.
The global vaccine group Gavi said on Monday it hopes to use $600 million in soon-to-be-restored U.S. funding to boost malaria and other vaccination efforts, as it also meets U.S. conditions over phasing out the preservative thimerosal in other vaccines in its portfolio.
